Example of International Journal of Clinical Oncology format
Recent searches

Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format Example of International Journal of Clinical Oncology format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

International Journal of Clinical Oncology — Template for authors

Publisher: Springer
Categories Rank Trend in last 3 yrs
Surgery #55 of 422 up up by 1 rank
Hematology #39 of 123 up up by 5 ranks
Oncology #142 of 340 down down by 2 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 706 Published Papers | 3275 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 18/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

Nature

Quality:  
High
CiteRatio: 16.0
SJR: 4.539
SNIP: 2.28
open access Open Access

Springer

Quality:  
High
CiteRatio: 6.3
SJR: 1.037
SNIP: 0.989
open access Open Access

Elsevier

Quality:  
High
CiteRatio: 3.4
SJR: 0.989
SNIP: 1.175
open access Open Access
recommended Recommended

Elsevier

Quality:  
High
CiteRatio: 12.1
SJR: 2.67
SNIP: 2.494

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

2.879

15% from 2018

Impact factor for International Journal of Clinical Oncology from 2016 - 2019
Year Value
2019 2.879
2018 2.503
2017 2.61
2016 2.064
graph view Graph view
table view Table view

4.6

2% from 2019

CiteRatio for International Journal of Clinical Oncology from 2016 - 2020
Year Value
2020 4.6
2019 4.5
2018 4.8
2017 4.2
2016 3.6
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has increased by 15% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 2% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.06

1% from 2019

SJR for International Journal of Clinical Oncology from 2016 - 2020
Year Value
2020 1.06
2019 1.074
2018 1.15
2017 0.99
2016 0.835
graph view Graph view
table view Table view

1.301

3% from 2019

SNIP for International Journal of Clinical Oncology from 2016 - 2020
Year Value
2020 1.301
2019 1.267
2018 1.157
2017 1.106
2016 0.879
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has decreased by 1% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 3% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

International Journal of Clinical Oncology

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Springer

International Journal of Clinical Oncology

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they...... Read More

Medicine

i
Last updated on
18 Jul 2020
i
ISSN
1341-9625
i
Impact Factor
High - 1.183
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
SPBASIC
i
Citation Type
Author Year
(Blonder et al, 1982)
i
Bibliography Example
Beenakker CWJ (2006) Specular andreev reflection in graphene. Phys Rev Lett 97(6):067,007, URL 10.1103/PhysRevLett.97.067007

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1007/S10147-017-1101-6
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer

Abstract:

Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms in women and the third largest number in men. Many new treatment methods have been developed over the last few decades. The Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 20... Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms in women and the third largest number in men. Many new treatment methods have been developed over the last few decades. The Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (JSCCR Guidelines 2010) have been prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding between health-care professionals and patients by making these Guidelines available to the general public. These Guidelines have been prepared by consensuses reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these Guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions held by the Guideline Committee, controversial issues were selected as Clinical Questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2010. read more read less

Topics:

Guideline (57%)57% related to the paper, Evidence-based medicine (52%)52% related to the paper, Informed consent (52%)52% related to the paper, Standard treatment (52%)52% related to the paper, Palliative care (51%)51% related to the paper
View PDF
1,709 Citations
open accessOpen access Journal Article DOI: 10.1007/S10147-015-0801-Z
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

Abstract:

Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms among women and the third largest number among men. Many new methods of treatment have been developed during recent decades. The Japanese Society for Cancer of the Colon and Rectum Guidelines 2014 ... Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms among women and the third largest number among men. Many new methods of treatment have been developed during recent decades. The Japanese Society for Cancer of the Colon and Rectum Guidelines 2014 for treatment of colorectal cancer (JSCCR Guidelines 2014) have been prepared as standard treatment strategies for colorectal cancer, to eliminate treatment disparities among institutions, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding among health-care professionals and patients by making these guidelines available to the general public. These guidelines have been prepared as a result of consensuses reached by the JSCCR Guideline Committee on the basis of careful review of evidence retrieved by literature searches and taking into consideration the medical health insurance system and actual clinical practice in Japan. They can, therefore, be used as a guide for treating colorectal cancer in clinical practice. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions of the Guideline Committee, controversial issues were selected as clinical questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories, on the basis of consensus reached by Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2014. read more read less

Topics:

Guideline (59%)59% related to the paper, Informed consent (54%)54% related to the paper, Standard treatment (53%)53% related to the paper, Cancer (52%)52% related to the paper, Colorectal cancer (50%)50% related to the paper
View PDF
675 Citations
Journal Article DOI: 10.1007/S10147-008-0798-7
Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version

Abstract:

Diagnostic and treatment strategies for gastrointestinal stromal tumors (GISTs) have evolved greatly since the introduction of molecularly targeted therapies. Although several clinical practice guidelines are extant, such as those published by the National Comprehensive Cancer Network and the European Society of Medical Oncol... Diagnostic and treatment strategies for gastrointestinal stromal tumors (GISTs) have evolved greatly since the introduction of molecularly targeted therapies. Although several clinical practice guidelines are extant, such as those published by the National Comprehensive Cancer Network and the European Society of Medical Oncology, it is not clear as to whether these are appropriate for clinical practice in Japan. Therefore, clinical practice guidelines for the optimal diagnosis and treatment of GIST tailored for the Japanese situation have often been requested. For this reason, the Japanese Clinical Practice Guideline for GIST was proposed by the GIST Guideline Subcommittee, with the official approval of the Clinical Practice Guidelines Committee for Cancer of the Japan Society of Clinical Oncology (JSCO), and was published after assessment by the Guideline Evaluation Committee of JSCO. The GIST Guideline Subcommittee consists of members from JSCO, the Japanese Gastric Cancer Association (JGCA), and the Japanese Study Group on GIST, with the official approval of these organizations. The GIST Guideline Subcommittee is not influenced by any other organizations or third parties. Revision of the guideline may be done periodically, with the approval of the GIST Guideline Subcommittee, either every 3 years or when important new evidence that might alter the optimal diagnosis and treatment of GIST emerges. Here we present the English version of the Japanese Clinical Practice Guideline for GIST prepared by the GIST Guideline Subcommittee. read more read less

Topics:

Guideline (63%)63% related to the paper, GiST (56%)56% related to the paper, Imatinib mesylate (54%)54% related to the paper
293 Citations
Journal Article DOI: 10.1007/S10147-004-0392-6
The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma.
Takashi Yamane, Akihiro Kaneko, Makoto Mohri

Abstract:

Recently, there has been increasing interest in treating intraocular retinoblastoma with systemic chemotherapy combined with focal laser therapy and cryotherapy instead of radiotherapy. We developed a system of selective ophthalmic arterial infusion (SOAI) therapy, administering melphalan, the agent which had the greatest eff... Recently, there has been increasing interest in treating intraocular retinoblastoma with systemic chemotherapy combined with focal laser therapy and cryotherapy instead of radiotherapy. We developed a system of selective ophthalmic arterial infusion (SOAI) therapy, administering melphalan, the agent which had the greatest effect on retinoblastoma in a clonogenic assay. The SOAI system consists of a combination of a micro-balloon, a guiding catheter, and a flushing hub. After selective catheterization to the cervical segment of the internal carotid artery by the guiding catheter, the micro-balloon was propelled to the portion just distal to the orifice of the ophthalmic artery. During temporary occlusion of the internal carotid artery, melphalan was infused from the introduced catheter tip. We treated 187 patients with intraocular retinoblastoma with SOAI; 563 SOAIs were performed for 610 eyes. The technical success rate was 97.51%. Fourteen examinations failed. No significant complication due to catheterization (including brain infarction) was detected. SOAI, using the balloon occlusion technique, is safe, and its use will prevent the side effects that occur with systemic chemotherapy, and eliminate the need for irradiation and enucleation. read more read less

Topics:

Intraocular Retinoblastoma (59%)59% related to the paper, Ophthalmic artery (56%)56% related to the paper, Internal carotid artery (54%)54% related to the paper, Infusion therapy (53%)53% related to the paper, Catheter (51%)51% related to the paper
263 Citations
open accessOpen access Journal Article DOI: 10.1007/S10147-016-0959-Z
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Junzo Hamanishi1, Masaki Mandai2, Noriomi Matsumura1, Kaoru Abiko1, Tsukasa Baba1, Ikuo Konishi1

Abstract:

Recent studies showed that tumor cells ‘edit’ host immunity in several ways to evade immune defenses in the tumor microenvironment. This phenomenon is called “cancer immune escape.” One of the most important components in this system is an immunosuppressive co-signal (immune checkpoint) mediated by the PD-1 receptor and its l... Recent studies showed that tumor cells ‘edit’ host immunity in several ways to evade immune defenses in the tumor microenvironment. This phenomenon is called “cancer immune escape.” One of the most important components in this system is an immunosuppressive co-signal (immune checkpoint) mediated by the PD-1 receptor and its ligand, PD-L1. PD-1 is mainly expressed on activated T cells, whereas PD-L1 is expressed on several types of tumor cells. Preclinical studies have shown that inhibition of the interaction between PD-1 and PD-L1 enhances the T-cell response and mediates antitumor activity. Several clinical trials of PD-1/PD-L1 signal-blockade agents have exhibited dramatic antitumor efficacy in patients with certain types of solid or hematological malignancies. In this review, we highlight recent clinical trials using anti-PD-1 or anti-PD-L1 antibodies against several types of malignancies, including a trial conducted in our department, and describe the clinical perspectives and issues regarding the PD-1/PD-L1 blockade in cancer treatment. read more read less

Topics:

Immune checkpoint (59%)59% related to the paper, Immunotherapy (56%)56% related to the paper, Tumor microenvironment (55%)55% related to the paper, Immune system (54%)54% related to the paper, Nivolumab (53%)53% related to the paper
View PDF
249 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for International Journal of Clinical Oncology.

It automatically formats your research paper to Springer formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

International Journal of Clinical Oncology format uses SPBASIC citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write International Journal of Clinical Oncology in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the International Journal of Clinical Oncology guidelines and auto format it.

2. Do you follow the International Journal of Clinical Oncology guidelines?

Yes, the template is compliant with the International Journal of Clinical Oncology guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in International Journal of Clinical Oncology?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the International Journal of Clinical Oncology citation style.

4. Can I use the International Journal of Clinical Oncology templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for International Journal of Clinical Oncology.

5. Can I use a manuscript in International Journal of Clinical Oncology that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper International Journal of Clinical Oncology that you can download at the end.

6. How long does it usually take you to format my papers in International Journal of Clinical Oncology?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in International Journal of Clinical Oncology.

7. Where can I find the template for the International Journal of Clinical Oncology?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per International Journal of Clinical Oncology's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the International Journal of Clinical Oncology's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. International Journal of Clinical Oncology an online tool or is there a desktop version?

SciSpace's International Journal of Clinical Oncology is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like International Journal of Clinical Oncology?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like International Journal of Clinical Oncology?”

11. What is the output that I would get after using International Journal of Clinical Oncology?

After writing your paper autoformatting in International Journal of Clinical Oncology, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is International Journal of Clinical Oncology's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for International Journal of Clinical Oncology?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for International Journal of Clinical Oncology. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In International Journal of Clinical Oncology?

The 5 most common citation types in order of usage for International Journal of Clinical Oncology are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the International Journal of Clinical Oncology?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per International Journal of Clinical Oncology's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download International Journal of Clinical Oncology in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in International Journal of Clinical Oncology Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to International Journal of Clinical Oncology formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template